Targeted Diagnostics Position Adarza’s AIR technology as a high-sensitivity, label-free platform ideal for companion diagnostic development and clinical assay integration, highlighting opportunities with pharmaceutical companies and CROs advancing personalized medicine.

Multiplex Expansion Emphasize the ability to detect hundreds of analytes in a single assay to potential customers in drug discovery and biomarker research, enabling more efficient assay development and accelerated discovery programs.

Strategic Partnerships Leverage past funding milestones and facility expansions to pursue partnerships with large biotechs and contract manufacturers seeking scalable, multiplexed proteomics solutions and co-development opportunities.

Growth via POCT Highlight the platform’s applicability from discovery to point-of-care use, enabling sales conversations with clinical labs and hospital systems pursuing rapid, multiplexed testing workflows.

SMB Growth Focus Target mid-size biotech startups and specialty diagnostics companies with state-of-the-art multiplex capabilities, leveraging the small team size as a nimble partner for flexible collaboration and quick pilots.